BACKGROUND: Adolescent marijuana use is associated with increased risk for schizophrenia. We previously reported that marijuana misuse in conjunction with specific cannabinoid receptor 1 (CNR1) genetic variants (rs12720071-G-allele carriers) contributed to white-matter (WM) brain volume deficits in schizophrenia patients. In this study, we assessed the influence of another cannabinoid-related gene, mitogen-activated protein kinase 14 (MAPK14), and potential MAPK14-CNR1 gene-gene interactions in conferring brain volume abnormalities among schizophrenia patients with marijuana abuse/dependence. MAPK14 encodes a member of the MAPK family involved in diverse cellular processes, including CNR1-induced apoptosis. METHOD: We genotyped 235 schizophrenia patients on nine MAPK14 tag single nucleotide polymorphisms (tSNPs). Approximately one quarter of the sample had marijuana abuse or dependence. Differential effects of MAPK14 tSNPs on brain volumes across patients with versus without marijuana abuse/dependence were examined using ANCOVA. RESULTS: Of the MAPK14 tSNPs, only rs12199654 had significant genotype effects and genotype × marijuana misuse interaction effects on WM volumes. rs12199654-A homozygotes with marijuana abuse/dependence had significantly smaller total cerebral and lobar WM volumes. The effects of MAPK14 rs12199654 on WM volume deficits remained significant even after controlling for the CNR1 rs12720071 genotype. There were significant main effects of the MAPK14 CNR1 diplotype and diplotype × marijuana interaction on WM brain volumes, with both genetic variants having additive contributions to WM volume deficits only in patients with marijuana misuse. CONCLUSIONS: Given that CNR1-induced apoptosis is preceded by increased MAPK phosphorylation, our study suggests that potential MAPK14-CNR1 gene-gene interactions may mediate brain morphometric features in schizophrenia patients with heavy marijuana use.
BACKGROUND: Adolescent marijuana use is associated with increased risk for schizophrenia. We previously reported that marijuana misuse in conjunction with specific cannabinoid receptor 1 (CNR1) genetic variants (rs12720071-G-allele carriers) contributed to white-matter (WM) brain volume deficits in schizophreniapatients. In this study, we assessed the influence of another cannabinoid-related gene, mitogen-activated protein kinase 14 (MAPK14), and potential MAPK14-CNR1 gene-gene interactions in conferring brain volume abnormalities among schizophreniapatients with marijuana abuse/dependence. MAPK14 encodes a member of the MAPK family involved in diverse cellular processes, including CNR1-induced apoptosis. METHOD: We genotyped 235 schizophreniapatients on nine MAPK14 tag single nucleotide polymorphisms (tSNPs). Approximately one quarter of the sample had marijuana abuse or dependence. Differential effects of MAPK14 tSNPs on brain volumes across patients with versus without marijuana abuse/dependence were examined using ANCOVA. RESULTS: Of the MAPK14 tSNPs, only rs12199654 had significant genotype effects and genotype × marijuana misuse interaction effects on WM volumes. rs12199654-A homozygotes with marijuana abuse/dependence had significantly smaller total cerebral and lobar WM volumes. The effects of MAPK14rs12199654 on WM volume deficits remained significant even after controlling for the CNR1rs12720071 genotype. There were significant main effects of the MAPK14CNR1 diplotype and diplotype × marijuana interaction on WM brain volumes, with both genetic variants having additive contributions to WM volume deficits only in patients with marijuana misuse. CONCLUSIONS: Given that CNR1-induced apoptosis is preceded by increased MAPK phosphorylation, our study suggests that potential MAPK14-CNR1 gene-gene interactions may mediate brain morphometric features in schizophreniapatients with heavy marijuana use.
Authors: Vincent A Magnotta; Greg Harris; Nancy C Andreasen; Daniel S O'Leary; William T C Yuh; Dan Heckel Journal: Comput Med Imaging Graph Date: 2002 Jul-Aug Impact factor: 4.790
Authors: M P Vawter; T Barrett; C Cheadle; B P Sokolov; W H Wood; D M Donovan; M Webster; W J Freed; K G Becker Journal: Brain Res Bull Date: 2001-07-15 Impact factor: 4.077
Authors: Eduardo Molina-Holgado; José M Vela; Angel Arévalo-Martín; Guillermina Almazán; Francisco Molina-Holgado; José Borrell; Carmen Guaza Journal: J Neurosci Date: 2002-11-15 Impact factor: 6.167
Authors: Jesse D Hinckley; Laura Saba; Kristen Raymond; Karsten Bartels; Jost Klawitter; Uwe Christians; Christian Hopfer Journal: Cannabis Cannabinoid Res Date: 2020-06-19
Authors: Mary S Mufford; Dan J Stein; Shareefa Dalvie; Nynke A Groenewold; Paul M Thompson; Neda Jahanshad Journal: Genome Med Date: 2017-11-27 Impact factor: 11.117
Authors: Błażej Misiak; Filip Stramecki; Łukasz Gawęda; Katarzyna Prochwicz; Maria M Sąsiadek; Ahmed A Moustafa; Dorota Frydecka Journal: Mol Neurobiol Date: 2017-08-18 Impact factor: 5.590